DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

NCT07288112 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Melanoma

Interventions

BIOLOGICAL: DOC1021
PROCEDURE: Tumor resection
DRUG: pIFN (peginterferon alfa-2a)

Sponsor

Diakonos Oncology Corporation